Results from subgroup analysis analyzing the efficacy, safety of dupilumab with or without concomitant TCS in patients with erythrodermic AD, from CCO
Efficacy, safety of baricitinib in patients with 1 or more atopic comorbidity at baseline in BREEZE-AD1 and BREEZE-AD2, from CCO
Effect of withdrawal and retreatment with upadacitinib during an interim analysis of the 88-week phase 2b trial, from CCO
Efficacy, safety of once-daily oral abrocitinib 200 mg and 100 mg vs placebo in patients aged ≥12 years with moderate to severe AD; atopic dermatitis conference coverage from CCO
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.